NASDAQ: VKTX

Viking Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for VKTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-4.67

Viking Therapeutics, Inc. (NASDAQ: VKTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 18:46 UTC.

What Viking Therapeutics, Inc. does

The FDA requires pharmaceutical companies to conduct preclinical laboratory tests and animal studies before submitting an Investigational New Drug application, which authorizes human clinical trials to proceed. Clinical trials progress through phases, beginning with Phase 1 studies in a small number of healthy subjects to assess safety and basic effects, followed by Phase 2 trials to evaluate effectiveness in a limited patient population, and Phase 3 trials in expanded patient populations to further establish efficacy and safety.

Summarized from Viking Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-05-26
EPS (TTM)	$-4.67

Charts

Charts are in the appInteractive charts for VKTX are available in Oxford Ledge.
Open VKTX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-07

2026-08-07DirectorAward6,333—
2026-08-07DirectorStock Option (Right to Buy)Award40,800—
2026-07-29President & CEOAward221,667—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC6,335,756$247.16M+5.9%
BlackRock, Inc.6,189,649$241.46M-10.0%
STATE STREET CORP5,606,394$218.71M+27.6%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-04-23AuditorChanges in registrant's certifying accountantMarcum LLPAuthoritativeSEC 8-K →
2021-01-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2018-01-23Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Can Viking Therapeutics Carve Out a Place in the Obesity Market?
zacks.com2026-10-20
Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Yahoo2026-10-20POS
Can Viking Therapeutics Carve Out a Place in the Obesity Market?
Yahoo2026-10-20
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
Yahoo2026-10-18POS
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Yahoo2026-10-16NEG

Questions this page answers

What does Viking Therapeutics, Inc. do?

When did VKTX last file with the SEC?

Viking Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-05-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 18:46 UTC. This page is also available as JSON at /api/data?ticker=VKTX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VKTX and 5,000+ tickers.

Create a free account — keep VKTX

For your agent

GET /api/data?ticker=VKTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt